Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.57 |
| ▸ | PPARG | P37231 | 6/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767235 | 1.00 | PPARA (0.57) | PPARAPPARGPTPN1CTSSCTSK | |
| SCHEMBL5007445 | 0.91 | PPARA (0.57) | PPARAPPARGPTPN1CTSSCTSK | |
| SCHEMBL5007446 | 0.91 | PPARA (0.57) | PPARAPPARGPTPN1CTSSCTSK | |
| SCHEMBL4768752 | 0.90 | PPARA (0.47) | PPARAPPARGPTPN1CTSSCTSK | |
| SCHEMBL6938507 | 0.90 | PPARA (0.47) | PPARAPPARGPTPN1CTSSCTSK | |
| SCHEMBL5007491 | 0.89 | PPARA (0.55) | PPARAPPARGPTPN1CTSSCTSK | |
| SCHEMBL5001277 | 0.89 | PPARA (0.55) | PPARAPPARGPTPN1CTSSCTSK | |
| SCHEMBL5007488 | 0.89 | PPARA (0.55) | PPARAPPARGPTPN1CTSSCTSK | |
| SCHEMBL5001273 | 0.89 | PPARA (0.55) | PPARAPPARGPTPN1CTSSCTSK | |
| SCHEMBL5004848 | 0.87 | PPARA (0.58) | PPARAPPARGPTPN1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2852591-A1 | L-MALATE SALT OF 2, 7 - DIAZA - SPIRO [4.5]DEC- 7 - YLE DERIVATIVES AND CRYSTALLINE FORMS THEREOF AS GHRELIN RECEPTOR AGONISTS | Novartis AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| US-20130331369-A1 | 3-Spirocyclic Piperidine Derivatives as Ghrelin Receptor Agonists | NOVARTIS AG (CH) | 2013-12-12 | — | — | US | disclosed |
| WO-2013164790-A1 | L-MALATE SALT OF 2, 7 - DIAZA - SPIRO [4.5 ] DEC- 7 - YLE DERIVATIVES AND CRYSTALLINE FORMS THEREOF AS GHRELIN RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2013-11-07 | — | — | WO | disclosed |
| US-20130296358-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2013-11-07 | — | — | US | disclosed |
| US-20130296358-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2013-11-07 | — | — | US | disclosed |
| US-8546416-B2 | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists | NOVARTIS AG (CH) | 2013-10-01 | — | — | US | disclosed |
| US-8546416-B2 | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists | NOVARTIS AG (CH) | 2013-10-01 | — | — | US | disclosed |
| WO-2012164473-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012164473-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-12-06 | — | — | WO | disclosed |
| US-20120302540-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| US-7396846-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1497317-B1 | DIPEPTIDIC GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060167268-A1 | Growth hormone secretagogues | ELI LILLY AND COMPANY, PATENT DIVISION, (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1497316-B1 | GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050240001-A1 | 2-(2-Amino-2-methylpropionylamino)-3-(2,6-difluoro-3-methylphenyl)methoxy propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; endogenous human growth hormone controller; non-peptidyl in nature, more metabolically stable | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| US-6673929-B2 | Process for preparing growth hormone secretagogues | PFIZER INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030158414-A1 | Process for preparing growth hormone secretagogues | RAQUALIA PHARMA INC. (JP) | 2003-08-21 | — | — | US | disclosed |
| US-6541634-B2 | Reacting a pyrazolo(4,3-a)pyridine compound with amine | PFIZER INC. | 2003-04-01 | — | — | US | disclosed |
| US-20020002283-A1 | Process for preparing growth hormone secretagogues | RAQUALIA PHARMA INC. (JP) | 2002-01-03 | — | — | US | disclosed |
| EP-1031575-A1 | Process for preparing growth hormone secretagogues | Pfizer Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331369-A1 | 3-Spirocyclic Piperidine Derivatives as Ghrelin Receptor Agonists | GIPR, GHSR, GLP1R | PPARA 93/4885PPARG 44/4885PTPN1 730/4885 |
| US-20020002283-A1 | Process for preparing growth hormone secretagogues | GHRHR, GHSR, PRLHR | PPARA 3080/4885PPARG 1843/4885PTPN1 2458/4885 |
| US-20130296358-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GIPR, GHSR, GLP1R | PPARA 93/4885PPARG 44/4885PTPN1 730/4885 |
| US-20120302540-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GIPR, GHSR, GLP1R | PPARA 93/4885PPARG 44/4885PTPN1 730/4885 |
| US-20030158414-A1 | Process for preparing growth hormone secretagogues | GHRHR, GHSR, PRLHR | PPARA 3080/4885PPARG 1843/4885PTPN1 2458/4885 |
| US-20060167268-A1 | Growth hormone secretagogues | GHSR, GHRHR, CRH | PPARA 1477/4885PPARG 385/4885PTPN1 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.